Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 87 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Midazolam infusion Clear all
Suspended Phase 2 Interventional

Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia

NCT04912115
View directory record Official record
Conditions
Dyskinesias, Movement Disorders, Central Nervous System Diseases, Nervous System Diseases, Neurologic Manifestations
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
PharmaTher Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Chula Vista, California • Fountain Valley, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 19, 2026, 11:18 AM EDT
Completed Not applicable Interventional Results available

Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression

NCT02522377
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Severe Depression
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 19, 2026, 11:18 AM EDT
Enrolling by invitation Phase 3 Interventional Accepts healthy volunteers

GA + ESP vs. SA + ESP in Lumbar Decompression Surgeries

NCT05444751
View directory record Official record
Conditions
Lumbar Disc Herniation, Lumbar Disc Disease, Lumbar Radiculopathy
Interventions
General anesthetic, SA + ESP
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 19, 2026, 11:18 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

NCT03358706
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg, Warfarin 10 mg, Vitamin K 10 mg, Omeprazole 20 mg, Dextromethorphan 30 mg, Caffeine 100 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Cypress, California • Miami Springs, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Oct 19, 2026, 11:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ketamine for Treatment of MS Fatigue

NCT03500289
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 19, 2026, 11:18 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

NCT02760615
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn Disease
Interventions
Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 19, 2026, 11:18 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Quelling of Excitotoxicity in Acute Stroke With Ketamine

NCT03223220
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Ketamine, Normal Saline, Midazolam injection
Drug · Other
Lead sponsor
Lower Merion Neurology Research Foundation
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 19, 2026, 11:18 AM EDT
Completed Phase 4 Interventional

Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy

NCT02193568
View directory record Official record
Conditions
Adult Brain Tumor
Interventions
Arm I (light sedation), Arm II (intubated general anesthesia), Arm II (intubated general anesthesia), Arm I (light sedation)
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 19, 2026, 11:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Memory Modulation by Pain During Anesthesia

NCT02515890
View directory record Official record
Conditions
Amnesia, Pain, Anesthesia
Interventions
Dexmedetomidine, Midazolam, Peripheral nerve stimulation, Ketamine
Drug · Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 39 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 19, 2026, 11:18 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Intravenous Ketamine in the Treatment of Obsessive-Compulsive Disorder

NCT01371110
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Wayne Goodman MD
Other
Eligibility
21 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 19, 2026, 11:18 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Sedatives on Tobacco Use Disorder Version 2

NCT05505630
View directory record Official record
Conditions
Tobacco Smoking
Interventions
Ketamine, Midazolam, Dexmedetomidine, Saline
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 19, 2026, 11:18 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy

NCT03889756
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine infusion, Midazolam infusion
Drug
Lead sponsor
Yale University
Other
Eligibility
13 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 19, 2026, 11:18 AM EDT
Completed Phase 2Phase 3 Interventional

Lorazepam Sedation for Critically Ill Children

NCT00109395
View directory record Official record
Conditions
Critical Illness
Interventions
Lorazepam, Midazolam, Lorazepam CI
Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
1 Day to 18 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 19, 2026, 11:18 AM EDT
Withdrawn Phase 4 Interventional

Post-Operative Pain Control in Opioid Tolerant Patients: Fentanyl Challenge Protocol Versus Standard of Care

NCT02324933
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Fentanyl
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 19, 2026, 11:18 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

NCT06943521
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, Nuclear Protein in Testis (NUT) Carcinoma
Interventions
MT-4561
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 19, 2026, 11:18 AM EDT
Completed Phase 4 Interventional

Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients?

NCT01791296
View directory record Official record
Conditions
Sleep Deprivation, Delirium
Interventions
Dexmedetomidine, Placebo
Drug · Other
Lead sponsor
Maisonneuve-Rosemont Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 19, 2026, 11:18 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age

NCT01159262
View directory record Official record
Conditions
Sedation
Interventions
Midazolam, Fentanyl/Morphine, Dexmedetomidine
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
28 Weeks to 44 Weeks
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
17
States / cities
Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 19, 2026, 11:18 AM EDT
Completed Phase 2 Interventional Results available

Optimization of IV Ketamine for Treatment Resistant Depression

NCT00768430
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 19, 2026, 11:18 AM EDT
Recruiting Phase 3 Interventional

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

NCT03016819
View directory record Official record
Conditions
Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
Interventions
AL3818, Dacarbazine, AL3818 or placebo, Midazolam 2 mg for CYP3A4 phenotyping, Digoxin (0.25mg), Rosuvastatin 10 mg tablet.
Drug
Lead sponsor
Advenchen Laboratories, LLC
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 19, 2026, 11:18 AM EDT
Withdrawn Not applicable Interventional

Dexmedetomidine Versus Pentobarbital for Pediatric Procedural Sedation

NCT00878345
View directory record Official record
Conditions
Sedation
Interventions
dexmedetomidine sedation protocol, pentobarbital sedation protocol
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Months to 6 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 19, 2026, 11:18 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

NCT04764851
View directory record Official record
Conditions
Drug-Interactions
Interventions
ecopipam HCl ~2mg/kg/day, Cohort 1 Probe Cocktail, Cohort 2 Probe Cocktail, Cohort 3 Probe Cocktail
Drug · Combination Product
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 19, 2026, 11:18 AM EDT
Completed Not applicable Interventional Results available

Pharmacokinetic Alterations During ECMO

NCT01938079
View directory record Official record
Conditions
Acute Respiratory Failure
Interventions
Ketamine, Sedative drug regimen
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 19, 2026, 11:18 AM EDT
Completed Not applicable Interventional Results available

Pilot Study on Pairing Sedation Strategies and Weaning

NCT02219659
View directory record Official record
Conditions
Acute Respiratory Failure
Interventions
Sedation Protocol with Daily Interruption, Sedation Protocol Without Daily Interruption, Fentanyl Push First
Drug
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 19, 2026, 11:18 AM EDT
Recruiting Phase 4 Interventional

Patient Quality of Recovery After TAVR With Different Sedation Regimens

NCT07556523
View directory record Official record
Conditions
Transcatheter Aortic Valve Replacement (TAVR), Aortic Valve Stenosis
Interventions
Propofol, Dexmedetomidine, Midazolam, Fentanyl
Drug
Lead sponsor
David Lyubashevsky
Other
Eligibility
18 Years to 90 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 19, 2026, 11:18 AM EDT